per-chart, page-609

Many think on here that I exaggerate my sp and MC
predictions:
Let me explain

A phase 2b molecule is worth in excess of $285 million


That’s around 35c per share

So IF our Tox and DMD is successful( ( meaning we replicate our end points PUL 2.0)

We move to a Phase 3
A molecule in P3 is worth $1248 million

The interesting thing here is .. that if the DMD results are better than expected PER w
ill go to the FDA .. for going into commercialisation $$

Once we get the green light from the FDA
PER has stated we could have a market of $1 billion US per annum and that’s only in DMD..








n